|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Collaboration Revenue | |||||
| Grant Revenue | |||||
| Total revenue | |||||
| Operating expenses: | |||||
| Research and development | |||||
| Acquired in-process research and development | |||||
| General and administrative | |||||
| Collaboration expense, net | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income : | |||||
| Other income, net | |||||
| Net loss before income taxes | |||||
| Provision for income taxes | |||||
| Net loss | |||||
| Foreign currency translation adjustment | |||||
| Unrealized gain (loss) on marketable securities | |||||
| Comprehensive loss | |||||
| Net loss per common share - basic | |||||
| Basic weighted-average common shares outstanding | |||||
| Net loss per common share - diluted | |||||
| Diluted weighted-average common shares outstanding |
Loading...